Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), BioNTech SE (BNTX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Coya Therapeutics, Inc. (COYA) and BioNTech SE (BNTX) with bullish sentiments.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Coya Therapeutics, Inc. (COYA)
In a report released today, Chad Messer from Lake Street maintained a Buy rating on Coya Therapeutics, Inc., with a price target of $17.00. The company’s shares closed last Thursday at $4.53.
According to TipRanks.com, Messer is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coya Therapeutics, Inc. with a $16.25 average price target.
See today’s best-performing stocks on TipRanks >>
BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE today and set a price target of $126.00. The company’s shares closed last Thursday at $91.98.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
BioNTech SE has an analyst consensus of Strong Buy, with a price target consensus of $137.06, a 50.0% upside from current levels. In a report issued on March 31, H.C. Wainwright also reiterated a Buy rating on the stock with a $130.00 price target.
Read More on COYA:
Disclaimer & DisclosureReport an Issue
- Coya Therapeutics announces publication of research on COYA 302
- Coya Therapeutics Announces Leadership Changes and New Director
- Coya Therapeutics Executive Chairman Howard Berman steps down
- 3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
- Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating
